On December 18, 2025 CARTemis Therapeutics (a Max Delbrück Center spin-off) reported the company and TQ Therapeutics are joining forces to explore CXCR5-targeted in vivo CAR-T therapies on the TQx CELLfinity platform. Together, TQx and CARTemis will collaborate on testing CARTemis’ first-in-class CAR constructs (including the CXCR5 lead asset), while TQx provides its in vivo CELLfinity delivery platform and process development expertise for efficient, clinical‑grade CAR‑T manufacturing. This collaboration aims to accelerate the translation of innovative CAR-T concepts into scalable, patient-ready therapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Press release, CARTemis Therapeutics, DEC 18, 2025, View Source;utm_medium=member_desktop&rcm=ACoAADkl3M8BNM0IYvrM85bmhQKKUuqeM5FeWhY [SID1234662192])